Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Barras

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
JCI Insight|June 26, 2019
RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancerOghenekevwe M Gbenedio, Caroline Bonnans, Delphine Grun, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signaturesDoga C Gulhan, Vinay Viswanadham, Francesc Muyas, et al.
The Journal of Clinical Investigation|February 5, 2020
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in miceSimone Ragusa, Borja Prat-Luri, Alejandra González-Loyola, et al.
Nature Cardiovascular Research|May 23, 2022
Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growthJeremiah Bernier-Latmani, Christophe Cisarovsky, Samantha Mahfoud, et al.
Nature Biotechnology|June 25, 2024
Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithmsRémy Pétremand, Johanna Chiffelle, Sara Bobisse, et al.
Nature Biotechnology|May 7, 2024
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithmsRémy Pétremand, Johanna Chiffelle, Sara Bobisse, et al.
Cancer Cell|June 12, 2019
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid TumorsDenarda Dangaj, Marine Bruand, Alizée J Grimm, et al.
Nature Cancer|September 22, 2023
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancerSara Bobisse, Valentina Bianchi, Janos L Tanyi, et al.
Nature|November 28, 2024
Cancer cells impair monocyte-mediated T cell stimulation to evade immunityAnais Elewaut, Guillem Estivill, Felix Bayerl, et al.
Cell Reports|July 21, 2021
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STINGMarine Bruand, David Barras, Marco Mina, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
JCI Insight|June 26, 2019
RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancerOghenekevwe M Gbenedio, Caroline Bonnans, Delphine Grun, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signaturesDoga C Gulhan, Vinay Viswanadham, Francesc Muyas, et al.
The Journal of Clinical Investigation|February 5, 2020
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in miceSimone Ragusa, Borja Prat-Luri, Alejandra González-Loyola, et al.
Nature Cardiovascular Research|May 23, 2022
Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growthJeremiah Bernier-Latmani, Christophe Cisarovsky, Samantha Mahfoud, et al.
Nature Biotechnology|June 25, 2024
Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithmsRémy Pétremand, Johanna Chiffelle, Sara Bobisse, et al.
Nature Biotechnology|May 7, 2024
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithmsRémy Pétremand, Johanna Chiffelle, Sara Bobisse, et al.
Cancer Cell|June 12, 2019
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid TumorsDenarda Dangaj, Marine Bruand, Alizée J Grimm, et al.
Nature Cancer|September 22, 2023
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancerSara Bobisse, Valentina Bianchi, Janos L Tanyi, et al.
Nature|November 28, 2024
Cancer cells impair monocyte-mediated T cell stimulation to evade immunityAnais Elewaut, Guillem Estivill, Felix Bayerl, et al.
Cell Reports|July 21, 2021
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STINGMarine Bruand, David Barras, Marco Mina, et al.
Pageof 5